Stridor

Global Botulinum Toxin Market Trajectory & Analytics, 2020-2022 & 2026 - Intense Competition Characterizes Botulinum Toxin Market - ResearchAndMarkets.com

Retrieved on: 
Friday, June 17, 2022
Other Health, General Health, Pharmaceutical, Fashion, Cosmetics, Retail, Science, Surgery, Biotechnology, FDA, Other Science, Health, Stridor, CAGR, Type, FDA, Obesity, Botulinum toxin, Spasm, Parkinson, Palatal myoclonus, Neck pain, Growth, Movement disorders, Stomach, BTX, Toxin (comics), Vocal cord dysfunction, Nystagmus, Torticollis, Cerebral palsy, Patient, Movement, Disorder, Scoliosis, Medical tourism, Canning, Pet, Pharmaceutical industry

The "Botulinum Toxin - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Botulinum Toxin - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Global market for Botulinum Toxin estimated at US$4.9 Billion in the year 2020, is projected to reach a revised size of US$7.9 Billion by 2026, growing at a CAGR of 8.2% over the analysis period.
  • Growth in the global market is driven by growing demand in medical/therapeutic and cosmetic applications.
  • Rapidly improving socio-economic conditions and proliferation of medical tourism, particularly in Asian countries, presents favorable prospects for botulinum toxin in Asia-Pacific region.

Myrtelle Inc. Announces Expansion of Its Pipeline with a Novel Gene Therapy Program for Pelizaeus-Merzbacher Disease (PMD)

Retrieved on: 
Wednesday, May 11, 2022
Science, Other Science, Biotechnology, Research, Health, Genetics, Clinical Trials, Other Health, Architecture, Disorder, Hope, Sex linkage, Pfizer, Mutation, Brain, Inc., MicroRNA, CNS, Mirna, Death, Secondary research, Phenotype, Patient, Doctor of Philosophy, Stridor, White matter, Neurodegeneration, Gene silencing, PLP1, Human, Pelizaeus–Merzbacher disease, ASPA, Therapy, Hypotonia, Pharmacology, Disease, Science, Kaay Raav Tumhi, Intellectual property, Life, Nystagmus, Canavan disease, Central nervous system, Cell, Myrtelle Canavan, PMD, Pharmaceutical industry, Copper, Vaccine, Tight junction protein 1

This duplication results in excessive Plp1 accumulation that disrupts proper myelin formation and triggers extensive loss of oligodendrocytes in the CNS.

Key Points: 
  • This duplication results in excessive Plp1 accumulation that disrupts proper myelin formation and triggers extensive loss of oligodendrocytes in the CNS.
  • Oligodendrocytes are the cells in the brain responsible for producing myelin the insulating material that enables proper neuronal function.
  • Myrtelle has built enabling technologies and capabilities in gene therapy for disorders involving oligodendrocytes and myelin production.
  • Myrtelle has an exclusive worldwide licensing agreement with Pfizer for its lead program in Canavan disease.

UPDATE - Y-mAbs Announces Pipeline Update

Retrieved on: 
Wednesday, December 15, 2021
Therapy, Melanoma, Doctor of Philosophy, Private Securities Litigation Reform Act, Cardiac arrest, Neoplasm, Bone marrow, MBA, Squamous cell carcinoma, Antibody, FDA, Neuroblastoma, Cancer, Stridor, Growth, Adult, Hospital, Wernicke encephalopathy, Atrium, SVP, Memorial Sloan Kettering Cancer Center, Safety, Risk, GLOBE, Sarcoma, Granulocyte-macrophage colony-stimulating factor, US Foods, Technology, COVID-19, Breast cancer, SEC, Research, Marketing, Coronavirus, DCH, MBBS, GD2, Failure, Government, MRCP, Company, All India Mahila Congress, Neurotoxicity, Naxitamab, Industry, Annual report, Neuropathic pain, MSK, Patient, Bronchospasm, Anaphylaxis, Transverse myelitis, Hypotension, Medical device, Pharmaceutical industry, MD

The Y-mAbs research and development day will feature presentations from oncology key opinion leaders (KOLs) Javier E. Oesterheld, M.D.

Key Points: 
  • The Y-mAbs research and development day will feature presentations from oncology key opinion leaders (KOLs) Javier E. Oesterheld, M.D.
  • An update on Y-mAbs broad and advanced product pipeline, including the Companys SADA Technology, will follow from Vignesh Rajah, MBBS, DCH, MRCP(UK), MBA, (SVP, Chief Medical Officer at Y-mAbs) and Steen Lisby, M.D., DMSc, (SVP, Chief Scientific Officer at Y-mAbs).
  • Dr. Lisby will present new details on the proposed mechanism of action for the SADA Technology.
  • The Company plans to file an Investigational New Drug Application (IND) with the US Food & Drug Administration (FDA) for GD2-SADA by the end of this year.

Y-mAbs Announces Pipeline Update

Retrieved on: 
Wednesday, December 15, 2021
Therapy, Melanoma, Doctor of Philosophy, Private Securities Litigation Reform Act, Cardiac arrest, Neoplasm, Bone marrow, MBA, Squamous cell carcinoma, Antibody, FDA, Neuroblastoma, Cancer, Stridor, Growth, Adult, Hospital, Wernicke encephalopathy, Atrium, SVP, Memorial Sloan Kettering Cancer Center, Safety, Risk, GLOBE, Sarcoma, Granulocyte-macrophage colony-stimulating factor, US Foods, Technology, COVID-19, Breast cancer, SEC, Research, Marketing, Coronavirus, DCH, MBBS, GD2, Failure, Government, MRCP, Company, All India Mahila Congress, Neurotoxicity, Naxitamab, Industry, Annual report, Neuropathic pain, MSK, Patient, Bronchospasm, Anaphylaxis, Transverse myelitis, Hypotension, Medical device, Pharmaceutical industry, MD

The Y-mAbs research and development day will feature presentations from oncology key opinion leaders (KOLs) Javier E. Oesterheld, M.D.

Key Points: 
  • The Y-mAbs research and development day will feature presentations from oncology key opinion leaders (KOLs) Javier E. Oesterheld, M.D.
  • An update on Y-mAbs broad and advanced product pipeline, including the Companys SADA Technology, will follow from Vignesh Rajah, MBBS, DCH, MRCP(UK), MBA, (SVP, Chief Medical Officer at Y-mAbs) and Steen Lisby, M.D., DMSc, (SVP, Chief Scientific Officer at Y-mAbs).
  • Dr. Lisby will present new details on the proposed mechanism of action for the SADA Technology.
  • Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy

Retrieved on: 
Tuesday, September 28, 2021
Mortality, Neck, Man, CRC, Arthralgia, Interstitial lung disease, Shock, Cardiac arrest, Arrhythmia, Death, Catherine Disher, Safety, Mutation, Sudden death, FOLFIRI, Diarrhea, Resuscitation, Colon, Coronary artery disease, Abdominal pain, BRAF, ILD, Adult, Heart, Dor, Disease, Pfizer, Hypotension, Organic acid, Magnesium, History, Bronchospasm, PFS, Myocardial infarction, Patient, Fatigue, Potassium, FDA, Cancer, Rectum, Nausea, ORR, Rash, Risk, HIV disease progression rates, Irinotecan, Arm, Appetite, Stridor, Pulmonary toxicity, Immunoglobulin E, Anaphylaxis, Calcium, Arrest, Airway obstruction, Encorafenib, Head, Cetuximab, Fluorouracil, Premedication, Colorectal cancer, KRAS, EGFR, Pharmaceutical industry, Medical device

Caution must be exercised with every ERBITUX infusion as infusion reactions may occur during or several hours following completion of the infusion.

Key Points: 
  • Caution must be exercised with every ERBITUX infusion as infusion reactions may occur during or several hours following completion of the infusion.
  • In patients requiring treatment for infusion reactions, monitor for more than 1 hour to confirm resolution of the reaction.
  • Interrupt the infusion and upon recovery, resume the infusion at a slower rate or permanently discontinue ERBITUX based on severity.
  • One patient with no prior history of coronary artery disease died one day after the last dose of ERBITUX.